JSPR, US4718712023

Jasper Therapeutics stock: Q3 net loss reaches USD 144.5 million

Published on 11/19/2026 at 02:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Jasper Therapeutics stock is in focus after the company reported a sharp quarterly loss. Kidney-study milestones are due in late 2026 and early 2027.

Jasper's Results And Pipeline

  • Cash and cash equivalents totaled USD 135.3 million at September 30, 2026.
  • Jasper completed enrollment in the first IgA nephropathy cohort and started additional kidney-disease cohorts.
  • Interim IgA nephropathy data are expected in the fourth quarter of 2026, with further updates planned for the first quarter of 2027.
JSPR, US4718712023, Illustration mit AI erstellt.

Jasper Therapeutics reported a third-quarter net loss of USD 144.455 million for the period ended September 30, 2026, compared with USD 18.736 million a year earlier. The company also advanced its kidney-disease pipeline, with interim IgA nephropathy data expected in the fourth quarter.

The results were published on November 16 in a Jasper Therapeutics release. Revenue reached USD 8.0 million, while costs of drug supplies and compounds totaled USD 7.993 million. Research and development expense was USD 8.327 million, and general and administrative expense was USD 6.359 million.

Acquisition Charge Drives Loss

The quarterly figures included USD 129.494 million of acquired in-process research and development expense linked to Jasper's Kira Pharmaceuticals acquisition. The company completed that all-stock transaction in July and said the related private placement generated approximately USD 132.0 million in gross proceeds.

Cash and cash equivalents stood at USD 135.3 million at September 30. The balance sheet also reflected the post-acquisition capital structure and the company's November 1-for-30 reverse stock split.

Kidney Program Sets Near-Term Milestones

Jasper completed enrollment in the first cohort of its Phase 2 renal basket study of vensobafusp alfa, also called KP104, in IgA nephropathy. It expects interim Stage 1 data in the fourth quarter of 2026 and updated data in the first quarter of 2027.

The company opened a focal segmental glomerulosclerosis expansion cohort, with first dosing expected in the first quarter of 2027. It also began enrollment in a C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis cohort and dosed the first patient in the latter indication. Initial data from a Phase 1/2 briquilimab study in severe combined immunodeficiency are also expected in the fourth quarter of 2026.

Clinical Biotechnology Focus

Jasper is a clinical-stage biotechnology company based in Redwood City, California, focused on therapies for immune-mediated diseases. Its pipeline includes vensobafusp alfa for complement-driven kidney disorders, briquilimab for stem-cell transplant conditioning and mast-cell diseases, and KP701 for autoantibody-mediated disorders. The company serves development segments spanning nephrology, hematopoietic stem-cell transplantation and immune-mediated disease treatment.

Jasper Therapeutics Company Facts

  • Company: Jasper Therapeutics, Inc.
  • ISIN: US4718712023
  • Ticker: JSPR
  • Primary exchange: Nasdaq
  • Business: Clinical-stage biotechnology for immune-mediated diseases
  • Cash and cash equivalents: USD 135.3 million as of September 30, 2026

The S&P 500 provides the broader U.S. market context for Jasper Therapeutics.

More news and analyses on Jasper Therapeutics stock are available on the company topic page.

Disclaimer...
en | US4718712023 | JSPR | boerse | 70533264 | bgmi